2GHANNOUM MA,KUHN DM.Voriconazole-better chances for patients with invasive mycoses[J].Eur J Med Res,2002,7 (5) :242-256.
3PFALLER MA,DIEKEMA DJ,JONES RN,et al. International surveillance of bloodstream infections due to Candida species:frequency of occurrence and in vitro susceptibilities to fluconazole,ravuconazole,and voriconazole of isolates collected from 1997 through 19
4ESPINEL-INGROFF A.In vitro activity of the new triazole voriconazole(UK-109,496)against opportunistic filamentous and dimorphic fungi and common and emerging yeast pathogens[J].J Clin Microbiol, 1998,36 ( 1 ) :198-202.
5ESPINEL-INGROFF A.In vitro fungicidal activities of voriconazole,itraconazole,and amphotericin B against opportunistic moniliaceous and dematiaceous fungi[J].J Clin MicrobioI,2001,39 (3) :954-958.
6CARRILLO AJ,GUARRO J.In vitro activities of four novel triazoles against Scedosporium spp[J].Antimicrob Agents Chemother, 2001,45 ( 7 ) :2151-2153.
7PURKINS L,WOOD N,GHAHRAMANI P, et al. Pharmacokinetics and safety of voriconazole following intravenous-to oral-dose escalation regimens[J].Antimicrob Agents Chemother, 2002,46 (8) :2546-2553.
8VENKATARAMANAN R, ZANG S,GAYOWSKI T, et al. Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes[J].Antimicrob Agents Chemother,2002,46 (9) :3091-3093.
9ROMERO A J, POGAMP PL,NILSSON LG, et al. Effect of voriconazole on the pharmacokinetics of cycrosporine in renal transplant patients[J].J Clin Pharmacol Ther,2002,71 (4) :226-234.
10DENNING DW, RIBAUD P, MILPIED N,et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis[J].Clin Infect Dis,2002,34 (5) :563-571.
